Thanks @hamsa. The BBC report is entirely consistent with the...

Thanks @hamsa. The BBC report is entirely consistent with the article referenced that was published in the Lancet refer start of thread. Re-posting the following observation from Post #: 45265855;

'According to the aforementioned article, a substantial proportion of patients who develop ARDS and survive the acute phase of the illness die as a result of progressive pulmonary fibrosis.'

I understand that approximately 20% of COVID-19 patients will contract acute respiratory distress syndrome (ARDS). The BBC report actually states that in the case of SARS and MERS between 20% to 60% of patients experienced symptoms consistent with pulmonary fibrosis. The aftermath is absolutely a real and pressing global health concern. The advent of AdAlta into the clinic will attract significant interest and the story will progress from COVID-19 vaccines to anti-fibrotic treatments. Calculate 20% of the global infection rate and you get a very big number and sadly it includes many people in the community who otherwise would never come across IPF.